Business Description
Imunon Inc
NAICS : 325412
SIC : 2834
ISIN : US15117N5032
Description
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.15 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 39.6 | |||||
| 3-Year EPS without NRI Growth Rate | 36.6 | |||||
| 3-Year FCF Growth Rate | 33.6 | |||||
| 3-Year Book Growth Rate | -40.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.51 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.59 | |||||
| 9-Day RSI | 59.93 | |||||
| 14-Day RSI | 53.23 | |||||
| 6-1 Month Momentum % | -38.69 | |||||
| 12-1 Month Momentum % | 4.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | |||||
| Quick Ratio | 2.3 | |||||
| Cash Ratio | 1.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51.3 | |||||
| Shareholder Yield % | 22.21 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -187.41 | |||||
| ROA % | -114.45 | |||||
| ROIC % | -688.2 | |||||
| ROC (Joel Greenblatt) % | -958.13 | |||||
| ROCE % | -182.07 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.52 | |||||
| Price-to-Tangible-Book | 1.5 | |||||
| EV-to-EBIT | -0.16 | |||||
| EV-to-Forward-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.17 | |||||
| EV-to-FCF | -0.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Price-to-Net-Cash | 3.06 | |||||
| Earnings Yield (Greenblatt) % | -625 | |||||
| FCF Yield % | -146.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Imunon Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.735 | ||
| Beta | 1.44 | ||
| Volatility % | 159.36 | ||
| 14-Day RSI | 53.23 | ||
| 14-Day ATR (€) | 0.036657 | ||
| 20-Day SMA (€) | 0.74525 | ||
| 12-1 Month Momentum % | 4.35 | ||
| 52-Week Range (€) | 0.438 - 3.7 | ||
| Shares Outstanding (Mil) | 14.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Imunon Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Imunon Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Imunon Inc Frequently Asked Questions
What is Imunon Inc(FRA:CBO)'s stock price today?
The current price of FRA:CBO is €0.80. The 52 week high of FRA:CBO is €3.70 and 52 week low is €0.44.
When is next earnings date of Imunon Inc(FRA:CBO)?
The next earnings date of Imunon Inc(FRA:CBO) is 2025-03-28 Est..
Does Imunon Inc(FRA:CBO) pay dividends? If so, how much?
Imunon Inc(FRA:CBO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers